AKT2-related familial partial lipodystrophy Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

1 event

Feb 2014

MYALEPT: FDA approved

Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for AKT2-related familial partial lipodystrophy.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

MYALEPT

(metreleptin)Orphan drug

Chiesi Farmaceutici S.p.A.

Leptin Analog [EPC]

12.1 Mechanism of Action Adipocytes store lipids to meet the fuel requirements of non-adipose tissues during fasting. In patients with generalized lip...

Approved Feb 2014FDA label ↗

View full treatment details on disease page →